1,050
Participants
Start Date
June 30, 2000
Primary Completion Date
April 30, 2007
Study Completion Date
October 31, 2009
Peginterferon alfa-2a + Ribavirin
Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight \<75 kg, \>75 kg) daily in two divided doses for 24 weeks
Peginterferon alfa-2a
90 mcg/week injection, for 3.5 years
University of Michigan, Ann Arbor
Saint Louis University, St Louis
UCHSC (University of Colorado), Denver
USC School of Medicine, Los Angeles
University of California-Irvine/VA Medical Center-Long Beach, Long Beach
University of Connecticut Health Center, Farmington
Lds, Niddk, Nih, Bethesda
Massachusetts General Hospital, Boston
UMass Memorial HealthCare, University Campus, Worcester
University of Texas Southwestern - Dallas, Dallas
Medical College of Virginia, Richmond
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
National Institute on Minority Health and Health Disparities (NIMHD)
NIH
National Cancer Institute (NCI)
NIH
Hoffmann-La Roche
INDUSTRY
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH